Results 101 to 110 of about 193,762 (235)

Protein Profile of Multiple Myeloma‐Derived Extracellular Vesicles for the Discovery of Novel Myeloma‐Related Biomarkers

Cancer Science, Volume 117, Issue 10, Page 2877-2890, October 2026.
Comparison of extracellular vesicles with parental cells through proteomic profiling, followed by an integrated bioinformatic pipeline including disease association and transcriptomic analyses, identifies candidate biomarkers for multiple myeloma. Among these, MIF emerges as a clinically relevant marker, supported by validation in patient samples and ...
Natalia Platonova, Gilda Aiello, Domenica Ronchetti, Valentina Citro, Rosanna Asselta, Lavinia Casati, Domenica Giannandrea, Elisa Taiana, Antonino Neri, Gloria Sini, Elisabetta Calzavara, Mauro Turrini, Alfonsina D'Amato, Raffaella Chiaramonte   +13 more
wiley   +1 more source

Junctional Adhesion Molecule‐A (JAM‐A) Associates With High‐Risk Disease in Multiple Myeloma Patients and a Structure‐Based Rationally‐Designed Peptide Inhibitor Attenuates Tumorigenic Features In Vitro and In Vivo

European Journal of Haematology, Volume 117, Issue 4, Page 995-1006, October 2026.
ABSTRACT Multiple myeloma (MM) is an incurable malignancy of terminally‐differentiated plasma cells that represents a major clinical challenge despite unprecedented therapeutic advances, particularly for patients with cytogenetically‐defined high‐risk MM (HR‐MM).
Niamh McAuley, Roisin McAvera, Dimitri Bong, Lara Donnelly, Izabela Cymer, Marian Brennan, Joanna Fay, Lance Hudson, John Quinn, Siobhan V. Glavey, Ann M. Hopkins   +10 more
wiley   +1 more source

Selective IL‐23 Inhibition in Conventional Treatment‐Refractory Pyoderma Gangrenosum: A Multicenter, Retrospective Study

International Journal of Dermatology, Volume 65, Issue 10, Page 2055-2065, October 2026.
The clinical effects of selective IL‐23 inhibition in refractory pyoderma gangrenosum, highlighting progressive ulcer healing, reduction in inflammation and pain, and steroid‐sparing effect, supporting the role of the IL‐23/Th17 axis as a therapeutic target.
Luca Bettolini, Carlo Alberto Maronese, Federica Derlino, Giovanni Genovese, Chiara Moltrasio, Luisa Sarno, Stefano Buffon, Bianca Cei, Giammarco Granieri, Valentina Dini, Marco Romanelli, Vincenzo Maione, Stefano Bighetti, Marina Venturini, Edoardo Cammarata, Paola Savoia, Antonio Di Guardo, Luigi Gargiulo, Ruggero Cascio Ingurgio, Antonio Costanzo, Lorenza Burzi, Claudia Leporati, Nunzia Di Cristo, Nicola Zerbinati, Alex G. Ortega‐Loayza, Angelo Valerio Marzano   +25 more
wiley   +1 more source

Circadian Deregulation in Multiple Myeloma: BMAL1/CLOCK Expression Patterns and Diagnostic Performance

International Journal of Laboratory Hematology, Volume 48, Issue 5, Page 1123-1132, October 2026.
ABSTRACT Background Circadian clock disruption has emerged as a relevant axis in cancer; however, the expression patterns and diagnostic relevance of BMAL1 and CLOCK in multiple myeloma (MM) remain insufficiently defined. Methods BMAL1 and CLOCK mRNA expression was quantified by RT‐qPCR in bone marrow samples from 46 newly diagnosed MM patients and 13 ...
Hamide Albayrak, Mustafa Ertan Ay, Anıl Tombak, Kenan Çevik, Özlem İzci Ay, Tuba Kabasakal, Mehmet Emin Erdal   +6 more
wiley   +1 more source

Integrating Gaucher disease (GD) into mainstream hematological curriculum training

HemaSphere, Volume 10, Issue 10, October 2026.
Colm Bradley, Argiris Symeonidis, Sam Salek, Nkemdirim Jacob   +3 more
wiley   +1 more source

Bridging gaps in diabetic neuropathy care: A Delphi‐based regional consensus from the Gulf Cooperation Council

Journal of Diabetes Investigation, Volume 17, Issue 10, Page 1643-1657, October 2026.
A three‐round Delphi consensus developed GCC‐specific, evidence‐based recommendations for diabetic peripheral neuropathy (DPN) and painful diabetic neuropathy (PND). The consensus emphasizes proactive screening, early multimodal management, and addressing regional barriers to improve early detection, optimize management, and enhance quality of life ...
Abdulrahman Alshaikh, Abdulnabi T Alattar, Ahmed Abdul Karim Hassoun, Afaf Alshammary, Hussein Elbadawi, Khaled Aldossari, Noor Al Busaidi, Saud Alsifri, Talal Muzaffar, Wiam I. Hussein, Christine Talaat, Abanoub Effat, Marwa Elsaghier, Rayaz A Malik   +13 more
wiley   +1 more source

Clinical management of clonal hematopoiesis

Cancer, Volume 132, Issue 18, 15 September 2026.
ABSTRACT Clonal hematopoiesis, particularly clonal hematopoiesis of indeterminate potential and clonal cytopenia of undetermined significance, is an age‐related premalignant condition characterized by the expansion of hematopoietic clones carrying somatic mutations.
Kelly S. Chien, Guillermo Garcia‐Manero   +1 more
wiley   +1 more source

Monoclonal gammopathy after intense induction immunosuppression in renal transplant patients.

, 1996
OBJECTIVES Incidence and risk factors of post-transplant monoclonal gammopathy were studied in renal transplant patients who received their grafts between 1982 and 1992 (n = 390 grafts).
Passweg J, Thiel G, Bock HA
core   +1 more source

Secondary monoclonal gammopathy of unknown significance with isotype switching after CAR T-cell therapy for multiple myeloma: A case report

Current Problems in Cancer: Case Reports
The incidence of secondary monoclonal gammopathy of undetermined significance is limited in patients with multiple myeloma post chimeric antigen receptor T-cell therapy.
Nilesh M. Kalariya, Hans C. Lee, Muzaffar H. Qazilbash, Krina K. Patel   +3 more
doaj   +1 more source

Renal Osteodystrophy in a Case of Suspected Plasma Cell Neoplasm

eJHaem, Volume 7, Issue 5, October 2026.
Timothy M. Hanley
wiley   +1 more source